Clinical and biochemical aspects of complex therapy of complicated forms of chronic venous insufficiency of lower extremities

The purpose of the study was to determine the contribution of RANKL/OPG transmembrane molecule system into the development of pathological arterial stiffness in rheumatoid arthritis (RA). RA patients (n=181) were randomized into 4 groups based on RF/ACCP (rheumatoid factor/antibodies to cyclic citrullinated peptide) positivity and disease duration (less than or more than 2 years). Serum osteoprotegerin (OPG) and soluble receptor activator of NF-kB ligand (sRANKL) concentrations, as well as pulse wave contour analysis were evaluated in all patients. The largest OPG level was detected in Group 1 patients; sRANKL concentration with maximal RANKL/OPG ratio was predominant in Group 4 patients. Prolonged course of RF/ACCP-seropositive RA was characterized by more significant arterial rigidity shifts (increases in augmentation (AIp), stiffness (SI), reflection (RI) indices). Correlation analysis revealed the presence of significant relations between the RANKL/OPG transmembrane molecule system and arterial rigidity parameters in RA.

arterial stiffness, pulse wave contour analysis, bone metabolism markers, osteoprotegerin, rheumatoid arthritis, sRANKL

1. Долженко А., Рихтер Т., Сагаловски С. Кальцификация сосудов, атеросклероз и потеря костной массы (остеопороз): новые патофизиологические механизмы и перспективы развития медикаментозной терапии // Альманах клинической медицины. - 2016. - Т. 44, № 4. - С. 513-534. - DOI: 10.18786/2072-0505-2016-44-4-513-534. [Dolzhenko A., Richter T., Sagalovsky S. Vascular calcification, atherosclerosis and bone loss (osteoporosis): new pathophysiological mechanisms and future perspectives for pharmacological therapy. Al’manakh klinicheskoy meditsiny. 2016; 44 (4): 513-534 (in Russ.)].

2. Парфёнов А.С. Экспресс-диагностика сердечно-сосудистых заболеваний // Мир измерений. - 2008. - № 6. - С. 74-82. [Parfyonov A.S. Express-diagnostics of cardiovascular diseases. Mir izmereniy. 2008; (6): 74-82 (in Russ.)].

3. Саранчина Ю.В., Килина О.Ю., Дутова С.В., Польща Н.Г., Ханарин Н.В., Кулакова Т.С. Методы изучения клеточного и молекулярного состава атеросклеротических бляшек: обзор литературы // Кардиоваскулярная терапия и профилактика. - 2017. - Т. 16, № 5. - С. 95-101. - DOI:10.15829/1728-8800-2017-5-95-101. [Saranchina Yu.V., Kilina O.Yu., Dutova S.V., Polshcha N.G., Khanarin N.V., Kulakova T.S. Methods for cellular and molecular compound of atherosclerotic plaques assessment: literary review. Kardiovaskulyarnaya terapiya i profilaktika. 2017; 16 (5): 95-101 (in Russ.)].

4. Скрипникова И.А., Алиханова Н.А., Абирова Э.С. Общие патогенетические механизмы атеросклероза и остеопороза: эластичность артериальной стенки и минеральная плотность кости в зависимости от некоторых параметров репликативного клеточного старения // Кардиоваскулярная терапия и профилактика. - 2014. - Т. 13, № 5. - С. 83-93. - DOI: 10.15829/1728-8800-2014-5-83-93. [Skripnikova I.A., Alikhanova N.A., Abirova E.S. Common pathogenetic mechanisms of atherosclerosis and osteoporosis: elasticity of arterial wall and mineral density of the bone according to some parameters of replication cell ageing. Kardiovaskulyarnaya terapiya i profilaktika. 2014; 13 (5): 83-93 (in Russ.)].

5. Alemao E., Cawston H., Bourhis F. Cardiovascular risk factor management in patients with RA compared to matched non-RA patients // Rheumatology. - 2016. - Vol. 55, N 5. - P. 809-816.

6. Boyce B.F., Xing L. Functions of RANKL/ RANK/OPG in bone modeling and remodeling // Arch. Biochem. Biophys. - 2008. - Vol. 473, N 2. - P. 139-146.

7. Caidahl K., Ueland T., Aukrust P. Osteoprotegerin: a biomarker with many faces // Atheroscler Thromb Vasc Biol. - 2010. - Vol. 30, N 9. - С. 1684-1686. - DOI: 10.1161/ATVBAHA.110.208843.

8. Collin-Osdoby P. Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin // Circ. Res. - 2004. - Vol. 95, N 11. - P. 1046-1057. - DOI: 10.1161/01.res.0000149165.99974.12.

9. Crepaldi G., Maggi S. Epidemiologic link between osteoporosis and cardiovascular disease // J. Endocrinol. Invest. - 2009. - Vol. 32, N 4 (Suppl). - P. 2-5.

10. Demer L.L., Tintut J. Vascular calcification: pathobiology of a multifaceted disease // Circulation. - 2008. - Vol. 117, N 22. - P. 2938-2948. - DOI: 10.1161/ CIRCULATIONAHA.107.743161.

11. Hofbauer L.C., Kuhne C.A., Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases // J Musculoskelet Neuronal Interact. - 2004. - Vol. 4, N 3. - P. 268-275.

12. Kanwar S.S., Stone G.W., Singh M. Acute coronary syndromes without coronary plaque rupture // Nat. Rev. Cardiol. - 2016. - Vol. 13, N 5. - P. 257-265. -DOI: 10.1038/ nrcardio.2016.19.

13. Kapelouzon A., Tsourelis L., Kaklamanis L., Kostakis A., Cokkinos D.V. Serum and tissue biomarkers in aortic stenosis // Global. Cardiol. Sci. Pract. - 2015. - N 4. - P. 49. DOI: 10.5339/gcsp.2015.49. eCollection 2015.

14. Kiechl S., Schett G., Wenning G. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease // Circulation. - 2004. - Vol. 109. - P. 2175-2180. - DOI: 10.1161/01.CIR.0000127957.43874.BB.

15. Kushlinskii N.E., Gershtein E.S., Timofeev Y.S. Osteoprotegerin (OPG) - receptor activator of NF-κB (RANK) - RANK ligand (RANKL) signaling system components and pro-inflammatory cytokines in blood serum of patients with primary bone neoplasms. Proceedings of 3rd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics, Sept. 01-03, 2015, Valencia, Spain // J. Pharmacogenomics Pharmacoproteomics. - 2015. - N 2. - P. 71.

16. Labovsky V., Vallone V.B., Martinez L.M., Otaegui J., Chasseing N.A. Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derivated factor-1 and their receptors in epithelial metastatic breast cancer cell lines // Cancer Cell Internat. - 2012. - Vol. 12, N 1. - P. 29. - DOI: 10.1186/1475-2867-12-29.

17. Langdahl B.L. New treatment of osteoporosis // Osteoporos Sarcopenia. - 2015. - Vol. 1, N 1. - P. 4-21. - DOI: 10.1016/J.AFOS.2015.07.007.

18. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., Rong J., Corey D., Hoffmann U., Fox C.S., Vasan R.S., Benjamin E.J., O'Donnell C.J., Kathiresan S. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality // Artherioscler. Thromb. Vasc. Biol. - 2010. - Vol. 30, N 9. - P. 1849-1854. - DOI: 10.1161/ATVBAHA.109.199661.

19. Lutgens S.P., Cleutjens K.B., Daemen M.J., Heeneman S. Cathepsin cysteine proteases in cardiovascular disease // FASEB J. - 2007. - Vol. 21, N 12. - P. 3029-3041. - DOI: 10.1096/fj.06-7924com.

20. Mikumo M., Okano H., Yoshikata R., Ishitani K., Ohta H. Association between lumber bone mineral density and vascular stiffness as assessed by pulse wave velocity in postmenopausal women // J. Bone Miner. Metab. - 2009. - N 27. - P. 89-94. - DOI: 10.1007/s00774-008-0014.

21. Ndip A., Williams A., Jude E.B., Serracino-Inglott F., Richardson S., Smyth J.V., Boulton A.J.M., Alexander M.Y. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy // Diabetes. - 2011. - Vol. 60, N 8. - P. 2187-2196. - DOI: 10.2337/db10-1220.

22. Nelson C.A., Warren J.T., Wang M. W-H., Teitelbaum S.L., Fremont D.H. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor // Structure. - 2012. - Vol. 20, N 11. - P. 1971-1982. - DOI: 10.1016/j. str.2012.08.030.

23. Papadopouli A.E., Klonaris C.N., Theocharis S.E. Role of OPG/RANKL/RANK axis on the vasculature // Histol. Histopathol. - 2008. - Vol. 23, N 4. - P. 497-506.

24. Periard D., Folly A., Meyer M.A. Aortic calcification and risk of osteoporotic fractures // Rev. Med. Suisse. - 2010. - Vol. 271, N 6. - P. 2200-2203.

25. Pettit A.R., Walsh N.C., Manning C., Goldring S.R., Gravallese E.M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis // Rheumatology (Oxford). - 2006. - N 45. - P. 1068-1076.

26. Sattler A.M., Schoppet M., Schaefer J.R., Hofbauer L.C. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease // Calcif. Tissue Int. - 2004. - N 74. - P. 103-106.

27. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function // Arterioscler. Thromb. Vasc. Biol. - 2002. - Vol. 22, N 4. - P. 549-553.

28. Tabas I., Garcia-Cardena G., Owens G.K. Recent insights into the cellular biology of atherosclerosis // J. Cell. Biol. - 2015. - Vol. 209, N 1. - P. 13-22. - DOI: 10.1083/jcb.201412052.

29. Van Compenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis // Atherosclerosis. - 2009. - Vol. 204, N 2. - P. 321-329. - DOI: 10.1016/j.atherosclerosis.2008.09.033.

30. Vik A., Mathiesen E.B., Brox J., Wilsgaard T., Njølstad I., Jørgensen L., Hansen J-B. Serum osteoprotegerin is a predictor for incident cardiovascular disease, and mortality in a general population: the Tromsö Study // J. Thromb. Haemostatic. - 2011. - Vol. 9, N 4. - P. 638-644. - DOI: 10.1111/j.153 8-7836.2011.04222.x.

31. Wattanakit K., Folsom A.R., Chambless L.E., Nieto F.J. Risk factors for cardiovascular event recurrence in the atherosclerosis risk in communities (ARIC) study // Am. Heart J. - 2005. - Vol. 149, N 4. - P. 606-612.

32. Wright H.L., McCarthy H.S., Middleton J., Marshall M.I. RANK, RANKL and osteoprotegerin in bone biology and disease // Curr. Rev. Musculoskelet. Med. - 2009. - Vol. 2, N 1. - P. 56-64. - DOI: 10.1007/ s12178-009-9046-7.

33. Zhu D., Mackenzie N.C., Farguharson C., MacRoe V.E. Mechanisms and clinical consequences of vascular calcification // Front. Endocrinol. (Lausanne). - 2012. - Vol. 3, N 1. - P. 95-110. - DOI: 10.3389/ fendo.2012.00095.